Abstract: Provided is a universal method for quantitatively determining therapeutic tumor necrosis factor (TNF)-alpha inhibitors in patient samples that is sufficiently sensitive for being able to detect all therapeutic TNF-alpha inhibitors.

Abstract: A vapor phase epitaxy method of growing a III-V layer with a doping profile that changes from a p-doping to an n-doping on a surface of a substrate or a preceding layer from the vapor phase from an epitaxial gas flow, at least one first precursor for an element of main group III, and at least one second precursor for an element of main group V. When a first growth height is reached, a first initial doping level is set by means of a ratio of a first mass flow of the first precursor to a second mass flow of the second precursor in the epitaxial gas flow, and subsequently, by stepwise or continuously changing the ratio of the first mass flow to the second mass flow and by stepwise or continuously increasing a mass flow of a third precursor for an n-type dopant in the epitaxial gas flow.

Abstract: A connecting assembly for the force-transmitting attachment of a first force-absorbing structural part to a second force-absorbing structural part includes tensile force-transmitters, shearing force-transmitters and compressive force-transmitters. The compressive force-transmitters include at least one compression element with a rod-like section. The rod-like section is provided for arrangement in a joint between the structural parts. The rod-like section is made from a metallic material. The rod-like section has a flow section with a constant cross-sectional area which is reduced compared with the rod-like section. A structure includes a connecting assembly.

Abstract: The present invention relates to an aqueous emulsion comprising a) a semifluorinated compound of formula I: CF3—(CF2)x—(CH2)y—CH3 ??(I) ?wherein x is an integer ranging from 1 to 8 and y is an integer ranging from 2 to 10, b) a triglyceride which is miscible with the semifluorinated compound at 20° C.; and c) an emulsifier.

Abstract: The invention is in the field of in vitro diagnostics and relates to a method for quantitatively determining therapeutic TNF-alpha inhibitors.

Abstract: The present invention relates to an aqueous formulation for use in diagnostic detection wherein the aqueous formulation is administered prior to the administration of a fluorinated contrast agent or composition comprising a fluorinated contrast agent as well as to a method of administration. The invention further relates to the use of said aqueous formulation for the diagnostic detection of inflammatory pathological conditions using MR imaging. In addition the invention relates to a kit as well as a diagnostic kit suitable for use in diagnostic detection.

Abstract: One aspect relates to an ablation electrode for high-frequency ablation in medical technology, whereby the ablation electrode includes a gold alloy. One aspect relates to a catheter tip for use with a catheter device, including an ablation electrode, as well as a catheter device for high-frequency ablation, including a catheter tip, as well as the use of an ablation electrode, a catheter tip or a catheter device for high-frequency ablation; as well as a process for production of an ablation electrode.

Abstract: A kit for calibrating a magnetic resonance imaging (MRI) system using defined concentration of 19F isotopes as well as a device for calibrating a MRI system using the kit. Further, a method for calibrating a MRI system employing the kit as well as to an entity comprising a defined concentration of 19F isotopes to be used in the calibration of a MRI system.

Abstract: A kit for calibrating a magnetic resonance imaging (MRI) system using defined concentration of 19F isotopes as well as a device for calibrating a MRI system using the kit. Further, a method for calibrating a MRI system employing the kit as well as to an entity comprising a defined concentration of 19F isotopes to be used in the calibration of a MRI system.

Abstract: One aspect relates to an ablation electrode for high-frequency ablation in medical technology, whereby the ablation electrode includes a gold alloy. One aspect relates to a catheter tip for use with a catheter device, including an ablation electrode, as well as a catheter device for high-frequency ablation, including a catheter tip, as well as the use of an ablation electrode, a catheter tip or a catheter device for high-frequency ablation; as well as a process for production of an ablation electrode.

Abstract: The present invention relates to an aqueous formulation for use in diagnostic detection wherein the aqueous formulation is administered prior to the administration of a fluorinated contrast agent or composition comprising a fluorinated contrast agent as well as to a method of administration. The invention further relates to the use of said aqueous formulation for the diagnostic detection of inflammatory pathological conditions using MR imaging. In addition the invention relates to a kit as well as a diagnostic kit suitable for use in diagnostic detection.

Abstract: The present invention relates to an aqueous emulsion comprising a) a semifluorinated compound of formula I: CF3—(CF2)x—(CH2)y—CH3(I) wherein x is an integer ranging from 1 to 8 and y is an integer ranging from 2 to 10, b) a triglyceride which is miscible with the semifluorinated compound at 20° C.; and c) an emulsifier.

Abstract: A catalyst comprising a plurality of catalyst gauzes that are arranged in series is provided. Each catalyst gauze is made of a first noble-metal-containing wire and a second noble-metal-containing wire which is embedded in the catalyst gauze and which gives the catalyst gauze a preferential direction. The catalyst gauzes according to the invention are arranged in series such that the angles between the preferential directions of neighboring catalyst gauzes ranges from 0° to 180°. The catalyst ensures a product yield that is reproducible over time and has a long service life.

Abstract: A catalyst comprising a plurality of catalyst gauzes that are arranged in series is provided. Each catalyst gauze is made of a first noble-metal-containing wire and a second noble-metal-containing wire which is embedded in the catalyst gauze and which gives the catalyst gauze a preferential direction. The catalyst gauzes according to the invention are arranged in series such that the angles between the preferential directions of neighboring catalyst gauzes are between 0° and 180°. The catalyst ensures a product yield that is reproducible over time and has a long service life.

Abstract: A catalyst comprising a plurality of catalyst gauzes that are arranged in series is provided. Each catalyst gauze is made of a first noble-metal-containing wire and a second noble-metal-containing wire which is embedded in the catalyst gauze and which gives the catalyst gauze a preferential direction. The catalyst gauzes according to the invention are arranged in series such that the angles between the preferential directions of neighboring catalyst gauzes ranges from 0° to 180°. The catalyst ensures a product yield that is reproducible over time and has a long service life.

Abstract: A catalyst comprising a plurality of catalyst gauzes that are arranged in series is provided. Each catalyst gauze is made of a first noble-metal-containing wire and a second noble-metal-containing wire which is embedded in the catalyst gauze and which gives the catalyst gauze a preferential direction. The catalyst gauzes according to the invention are arranged in series such that the angles between the preferential directions of neighboring catalyst gauzes are between 0° and 180°. The catalyst ensures a product yield that is reproducible over time and has a long service life.